Clinical trials: Nervous System Cancer
Brain and Central Nervous System Tumors, Metastatic Cancer
Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of carmustine followed by surgery in treating patients…
- Trial name
- NCT00009854
- Testing
- carmustine in ethanol, conventional surgery
- Where
- 2 sites in United States
- Sponsor
- Direct Therapeutics
Bone Metastasis, Cancer Pain
Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy
The purpose of this study is to determine whether tanezumab is effective in the treatment of cancer pain due to bone metastasis in patients already taking background opioid therapy.
- Trial name
- NCT02609828
- Testing
- Tanezumab
- Where
- 89 sites in Argentina, Australia and 14 more
- Volunteers
- 156 people
- Sponsor
- Pfizer
Cerebral Palsy (CP), Oncology
Acceptability and Tolerance Study of Bolus Tube Feed With Food Blends
This is a prospective acceptability study to evaluate the gastrointestinal tolerance and compliance of a bolus tube feed over a 28 -day period for up to 50 participants.
- Trial name
- Blends (NCT07341464)
- Testing
- Tube feed
- Where
- 2 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- Société des Produits Nestlé (SPN)
Liver Cancer, Pancreas Cancer
A Clinical Trial to Evaluate Safety and Efficacy of Endovascualr Denervation in Treatment of Cancer Pain
A prospective, multicenter, self-control clinical trial aim to enroll 110 patients suffered from upper abdominal (liver, pancreas, stomach, etc.) cancers .
- Conditions
- Liver Cancer, Pancreas Cancer, Stomach Cancer, Bile Duct Cancer
- Trial name
- NCT04014478
- Testing
- Endovascular Denervation
- Volunteers
- 110 people
- Sponsor
- Shanghai Golden Leaf MedTec Co. Ltd
Generalized Myasthenia Gravis
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
This study is researching the experimental drugs called pozelimab and cemdisiran, and cemdisiran monotherapy. The study is focused on patients with generalized Myasthenia Gravis (gMG).
- Trial name
- NIMBLE (NCT05070858)
- Testing
- Pozelimab + Cemdisiran, Cemdisiran, Pozelimab
- Where
- 116 sites in United States, Belgium and 17 more
- Volunteers
- 288 people
- Sponsor
- Regeneron Pharmaceuticals
Growth Hormone Deficiency, Neoplasms
A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters
The aim of this study is to look at the long-term safety and clinical parameters of somapacitan in paediatric participants with growth hormone deficiency under routine clinical practice conditions.
- Conditions
- Growth Hormone Deficiency, Neoplasms, Diabetes Mellitus Type 2
- Trial name
- NCT06709040
- Testing
- Somapacitan
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- Novo Nordisk A/S
Advanced Solid Malignancy, Safety and Tolerability
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
This study is designed to investigate the safety and tolerability of a new drug, AZD5363, in patients with advanced cancer - and to identify a dose and schedule that can be used in the future.
- Conditions
- Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics, Pharmacodynamics
- Trial name
- NCT01226316
- Testing
- AZD5363
- Where
- 34 sites in United States, Canada and 8 more
- Volunteers
- 285 people
- Sponsor
- AstraZeneca
Tuberous Sclerosis
Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B)
To assess preliminary safety and efficacy of ganaxolone as adjunctive therapy for the treatment of primary seizure types in patients with genetically- or clinically-confirmed TSC-related epilepsy through the end of the 12 week…
- Trial name
- TSC (NCT04285346)
- Testing
- Ganaxolone
- Where
- 7 sites in United States
- Volunteers
- 23 people
- Sponsor
- Marinus Pharmaceuticals
Breast Cancer, Hypercalcemia of Malignancy
Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Zoledronate may prevent bone loss and stop the growth of tumor cells in bone.
- Conditions
- Breast Cancer, Hypercalcemia of Malignancy, Metastatic Cancer, Pain
- Trial name
- NCT00060138
- Testing
- monoclonal antibody CAL, zoledronic acid
- Where
- United States
- Sponsor
- Chugai Pharmaceutical
Generalized Myasthenia Gravis (gMG)
An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis
This is a Phase Ib, open-label, dose-escalation, single-center/multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of multiple doses of EA5 (a humanized…
- Trial name
- NCT07818291
- Testing
- EA5
- Where
- 2 sites in China
- Volunteers
- 18 people
- Sponsor
- Shanghai Lanyi Therapeutics Co., Ltd.
Brain Tumor, Glioma, Malignant
Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO)
Pear Bio has developed a 3D microtumor assay and computer vision pipeline through which the response of an individual patient's tumor to different anti-cancer regimens can be tested simultaneously ex vivo.
- Conditions
- Brain Tumor, Glioma, Malignant, Ependymoma, Oligodendroglioma
- Trial name
- PEAR-GLIO (NCT06038760)
- Testing
- Resection
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Ourotech, Inc.
Pain
Safety and Efficacy Study of Osmotic Release Oral System (OROS) Hydromorphone in Participants With Cancer Pain
The purpose of this study is to evaluate the effectiveness and safety of Osmotic Release Oral System (OROS) hydromorphone using standardized conversion from prior opioid therapy among participants with cancer pain.
- Trial name
- NCT01648699
- Testing
- Osmotic Release Oral System (OROS) hydromorphone
- Volunteers
- 20 people
- Sponsor
- Janssen Pharmaceutica
Glioblastoma, Astrocytoma, Grade IV
A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM
The purpose of the Cerebral EDV study is to determine the safety and tolerability of EGFR(V)-EDV-Dox in order to establish the best dose level to be used in future studies.
- Trial name
- CerebralEDV (NCT02766699)
- Testing
- EGFR(V)-EDV-Dox
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Engeneic Pty Limited
Acromegaly
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
This is a phase IIIb multicenter, open-label; single arm study to evaluate the efficacy and safety of pasireotide LAR 40 mg and 60 mg in patients with inadequately controlled acromegaly with maximal approved doses of first…
- Trial name
- NCT02354508
- Testing
- Pasireotide LAR
- Where
- 50 sites in Argentina, Belgium and 13 more
- Volunteers
- 123 people
- Sponsor
- Novartis Pharmaceuticals
Breakthrough Pain, Cancer
Efficacy and Tolerability of Intranasal Fentanyl Spray for the Treatment of Breakthrough Pain in Cancer Patients Older Than 18 Years
The aim of the study was to evaluate the safety and efficacy of intranasal fentanyl spray in cancer patients over four weeks, especially during cancer-related breakthrough pain (BTP) attacks.
- Trial name
- GENISIS (NCT00994760)
- Testing
- Instanyl (Intranasal Fentanyl)
- Where
- 168 sites in Germany
- Volunteers
- 131 people
- Sponsor
- Takeda
Myasthenia Gravis, Generalized
A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
The purpose of this Phase 3 study is to demonstrate the efficacy, safety, and tolerability of claseprubart in participants with generalized myasthenia gravis (gMG).
- Trial name
- NCT07647510
- Testing
- Claseprubart
- Where
- 4 sites in United States
- Volunteers
- 195 people
- Sponsor
- Dianthus Therapeutics
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD
The primary purpose of this study is to evaluate the efficacy and safety of ravulizumab for the treatment of adult participants with NMOSD.
- Trial name
- NCT04201262
- Testing
- Ravulizumab
- Where
- 41 sites in United States, Australia and 11 more
- Volunteers
- 58 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Cancer Pain
35kDa Hyaluronan Fragment Treatment of Colorectal and Rectal Cancer
HA35 (Bioactive HA or B-HA or HA35) have good tissue permeability (B-HA injection, Ministry of Health, Registration number L20200708MP07707).
- Trial name
- NCT06209970
- Testing
- HA35
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Nakhia Impex LLC
Myasthenia Gravis, Generalized Myasthenia
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis
Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106.
- Conditions
- Myasthenia Gravis, Generalized Myasthenia, AChR Myasthenia Gravis, MuSK MG
- Trial name
- NCT06106672
- Testing
- CNP-106
- Where
- 17 sites in United States
- Volunteers
- 54 people
- Sponsor
- COUR Pharmaceutical Development Company, Inc.
Breast Cancer
Biomarker Testing and Treatment Patterns Among Patients With PIK3CA Mutation in Advanced Breast Cancer
This was a retrospective observational study of patients with advanced breast cancer (BC). This non-interventional study was conducted using discrete structured data and medical record abstraction, if needed, from patients…
- Trial name
- NCT05982886
- Where
- United States
- Volunteers
- 1,093 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.